Lipoamide Attenuates Hypertensive Myocardial Hypertrophy Through PI3K/Akt-Mediated Nrf2 Signaling Pathway
© 2024. The Author(s)..
The process of myocardial hypertrophy in hypertension can lead to excessive activation of oxidative stress. Lipoamide (ALM) has significant antioxidant and anti-inflammatory effects. This study aimed to investigate the effects of ALM on hypertension-induced cardiac hypertrophy, as well as explore its underlying mechanisms. We evaluated the effects of ALM on spontaneously hypertensive rats and rat cardiomyocytes treated with Ang II. We found that ALM was not effective in lowering blood pressure in SHR, but it attenuated hypertension-mediated cardiac fibrosis, oxidative stress, inflammation, and hypertrophy in rats. After that, in cultured H9C2 cells stimulated with Ang II, ALM increased the expression of antioxidant proteins that were decreased in the Ang II group. ALM also alleviated cell hypertrophy and the accumulation of ROS, while LY294002 partially abrogated these effects. Collectively, these results demonstrate that ALM could alleviate oxidative stress in cardiac hypertrophy, potentially through the activation of the PI3K/Akt-mediated Nrf2 signaling pathway.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of cardiovascular translational research - (2024) vom: 09. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cao, Hongjuan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiac hypertrophy |
|---|
| Anmerkungen: |
Date Revised 09.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s12265-024-10488-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368243303 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368243303 | ||
| 003 | DE-627 | ||
| 005 | 20240209232242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240209s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12265-024-10488-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1285.xml |
| 035 | |a (DE-627)NLM368243303 | ||
| 035 | |a (NLM)38334841 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cao, Hongjuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipoamide Attenuates Hypertensive Myocardial Hypertrophy Through PI3K/Akt-Mediated Nrf2 Signaling Pathway |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a The process of myocardial hypertrophy in hypertension can lead to excessive activation of oxidative stress. Lipoamide (ALM) has significant antioxidant and anti-inflammatory effects. This study aimed to investigate the effects of ALM on hypertension-induced cardiac hypertrophy, as well as explore its underlying mechanisms. We evaluated the effects of ALM on spontaneously hypertensive rats and rat cardiomyocytes treated with Ang II. We found that ALM was not effective in lowering blood pressure in SHR, but it attenuated hypertension-mediated cardiac fibrosis, oxidative stress, inflammation, and hypertrophy in rats. After that, in cultured H9C2 cells stimulated with Ang II, ALM increased the expression of antioxidant proteins that were decreased in the Ang II group. ALM also alleviated cell hypertrophy and the accumulation of ROS, while LY294002 partially abrogated these effects. Collectively, these results demonstrate that ALM could alleviate oxidative stress in cardiac hypertrophy, potentially through the activation of the PI3K/Akt-mediated Nrf2 signaling pathway | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cardiac hypertrophy | |
| 650 | 4 | |a Lipoamide | |
| 650 | 4 | |a Oxidative stress | |
| 650 | 4 | |a PI3K/Akt | |
| 700 | 1 | |a Zhao, Lina |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Chunyan |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Weidan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Aiyue |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Quanfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yueyao |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Yubing |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Liu |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Dandan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Sha |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Bei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cardiovascular translational research |d 2008 |g (2024) vom: 09. Feb. |w (DE-627)NLM18709375X |x 1937-5395 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:09 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12265-024-10488-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 09 |c 02 | ||